Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 466 AL 480

Micro- and Nanoplastics and Functional Nutrients in Human Health: Epigenetic Mechanisms and Cellular Resilience Signaling in Brain Insulin Resistance and the Risk of Alzheimer's Disease

Lombardo C, Musso N, Bonacci PG, Lupo G, Anfuso CD, Di Fatta E, Ferri R, Majzúnová M, Scuto MC, Trovato Salinaro A.

Int J Mol Sci. 2025 Dec 23;27(1):169. doi: 10.3390/ijms27010169.

Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia

Singhal T, Cicero S, Gale SA, Horan N, Dubey S, Marshall GA, Weiner HL.

Clin Nucl Med. 2025 Aug 1;50(8):756-757. doi: 10.1097/RLU.0000000000005955. Epub 2025 May 13.

Multiple ischemic strokes in a patient treated with Lecanemab: a case report

Alammar H, Diallo M, Llano DA.

Neurocase. 2025 Dec;31(6):295-300. doi: 10.1080/13554794.2025.2566151. Epub 2025 Oct 16.

Endoscopic Retrieval of Ingested Button Battery From a Colonic Diverticulum in an Alzheimer's Patient: A Case Report

Hizukuri K, Fujita Y, Amagai T.

Am J Case Rep. 2025 Dec 3;26:e949004. doi: 10.12659/AJCR.949004.

Differences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI

Hammers DB, Eloyan A, Thangarajah M, Taurone A, Beckett L, Gao S, Polsinelli AJ, Kirby K, Dage JL, Nudelman K, Aisen P, Reman R, La Joie R, Lagarde J, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Grant I, Rogalski E, Johnson ECB, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium 1 for the Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2025 Jan;21(1):e14218. doi: 10.1002/alz.14218. Epub 2024 Dec 23.

Identification of the binding site and immunoreactivity of anti-Aβ antibody 11A1: Comparison with the toxic conformation-specific TxCo-1 antibody

Fukui R, Hafizal U, Kageyama Y, Irie Y, Matsushima Y, Hosoi K, Nakayama T, Kaneda D, Hashizume Y, Miki K, Kita A, Mukaisho KI, Kushima R, Tooyama I, Irie K.

Biochem Biophys Res Commun. 2025 Apr 12;758:151655. doi: 10.1016/j.bbrc.2025.151655. Epub 2025 Mar 17.

Comparing clinical features of behavioral variant frontotemporal dementia and Alzheimer's disease using network analysis

Goodwin GJ, Mehrzad S, Cummings JL, Renn BN, Kinney JW, John SE.

Alzheimers Dement. 2025 Jun;21(6):e70361. doi: 10.1002/alz.70361.

Comparing levetiracetam and zonisamide effects on rivastigmine anti-Alzheimer's activity in aluminum chloride-induced Alzheimer's-like disease in rats: Impact on α7 nicotinic acetylcholine receptors and amyloid β

Abdel-Aal RA, Meligy FY, Maghraby N, Sayed N, Mohamed Ashry IE.

Brain Res. 2025 May 15;1855:149573. doi: 10.1016/j.brainres.2025.149573. Epub 2025 Mar 15.

Clinical trials targeting tau should be halted

Olluri A.

J Clin Neurosci. 2025 Apr;134:111101. doi: 10.1016/j.jocn.2025.111101. Epub 2025 Feb 4.

Special Issue: "New Trends in Alzheimer's Disease Research: From Molecular Mechanisms to Therapeutics: 2nd Edition"

Cacabelos R.

Int J Mol Sci. 2025 Jul 25;26(15):7175. doi: 10.3390/ijms26157175.

Donanemab: The dawn of disease-modifying treatment for Alzheimer's disease in Australia

Loi SM, Kang MJ.

Australas Psychiatry. 2025 Aug;33(4):599-602. doi: 10.1177/10398562251355157. Epub 2025 Jun 23.

History repeats itself: A new trivializing term for a potentially life-threatening side effect of antibody Alzheimer's disease therapy

Høilund-Carlsen PF, Barrio JR.

J Alzheimers Dis. 2025 Aug;106(3):925-927. doi: 10.1177/13872877251350295. Epub 2025 Jun 19.

Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease

Rosen J, Jessen F.

J Prev Alzheimers Dis. 2025 Apr;12(4):100102. doi: 10.1016/j.tjpad.2025.100102. Epub 2025 Feb 25.

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review

Wang Y, Yu Q, Chen B, Zhou J, Li Z, Liao W, Liu J, Yang A.

BMC Neurol. 2025 Jul 7;25(1):281. doi: 10.1186/s12883-025-04302-5.

VEGFB is a potential therapeutic target for Alzheimer's disease: Insights from integrative multi-omics analysis

Ye H, Zhuang C, Jin Z, Hu Y, He J, Yu Q, Hu H, Zheng Y.

J Alzheimers Dis. 2025 Dec;108(3):1073-1087. doi: 10.1177/13872877251385244. Epub 2025 Oct 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias